Project Grant R01HL184047
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $858K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Utah $231,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a meta-analysis of randomized controlled trials evaluating decision aids for stroke prevention in atrial fibrillation. The research synthesizes patient-level data from three large randomized controlled trials to quantify the overall effectiveness of decision aids on patient-centered and clinical outcomes,...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $242,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2025 through June 30, 2027. This award funds research examining the relationship between atrial fibrillation (AF), oral anticoagulation therapy, and retinal stroke (central retinal artery occlusion) using an instrumental variable...
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts Medical School $1,281,208 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thromboxane A₂ generation as a biomarker and mediator of heart failure risk. The award is a Project Grant with assistance type classified as R01HL185859. The research measures urinary thromboxane B₂ metabolites indexed to renal function (TXB₂-M_GFR) across approximately 17,000...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $231,000 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a risk prediction tool for thromboembolism in heart failure patients without atrial fibrillation. The project will integrate clinical variables with cardiovascular magnetic resonance biomarkers to create the first comprehensive risk stratification score for incident ischemic stroke...
- The National Heart, Lung, and Blood Institute awarded Northwestern University $440,000 on September 1, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) for the SPARTACUS project, a two-year effort to develop and validate an artificial intelligence tool that predicts stroke risk in atrial fibrillation patients taking anticoagulant medications. Northwestern will develop an advanced AI system called MIST-MAMBA that processes multiple data types—cardiac ultrasound, heart rhythm recordings,...
- The National Heart, Lung, and Blood Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $823,576 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate an electronic health record-embedded shared decision-making intervention for improving statin prescribing and adherence in cardiovascular disease prevention. The recipient will conduct a randomized trial of CV Prevention Choice, a next-generation...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded The Washington University $272,125 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to refine and pilot-test the PACE (Process for Adopting Clinical Evidence) tool, a digital implementation science platform designed to help hospital units identify and substitute low-value clinical practices with evidence-based alternatives. The project targets unnecessary procedures that expose patients to avoidable...